logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

First market approval in Japan for LIXIANA(®) (Edoxaban)

Global phase III trial with selective c-MET inhibitor tivantinib (ARQ 197) starts enrolling patients

Daiichi Sankyo offers assistance to victims of the Great East Japan earthquake

Daiichi Sankyo contributes to relief efforts for Japan earthquake victims

Plexxikon Inc. To Join Daiichi Sankyo Group

Daiichi Sankyo and ArQule enroll first non-small cell lung cancer patient into global phaseIII trial

Edoxaban demonstrates superior efficacy in preventing VTE after total HIP replacement

Daiichi Sankyo completes enrollment of the Edoxaban global phase III engage AF-TIMI 48 study

Daiichi Sankyo raised its profit forecast by almost 18%

AstraZeneca and Daiichi Sankyo announce Co-promotion agreement for Esomeprazole (Nexium)